What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?

Carroll, C, Houten, R ORCID: 0000-0002-4315-7732, Boland, A ORCID: 0000-0002-5435-8644, Kaltenthaler, E and Dickson, RC ORCID: 0000-0003-1416-0913 (2017) What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY? Value in Health, 21 (3). pp. 341-350.

Text
Corrected proof_Carrol_2017.pdf - Author Accepted Manuscript
Download (877kB)

Official URL: https://www.valueinhealthjournal.com/article/S1098...

Abstract

Background The National Institute for Health and Care Excellence has recently proposed that company submissions with a base-case incremental cost-effectiveness ratio (ICER) of less than £10,000/quality-adjusted life-year (QALY) might be eligible for a “fast-track” appraisal. Objectives To explore outcomes relating to previously conducted single-technology appraisals (STAs) with base-case ICERs of less than £10,000/QALY. Methods All STAs with published guidance from 2009 to 2016 were included; those with company base-case ICERs of less than £10,000/QALY were identified and analyzed. A secondary analysis was also conducted for those with a company base-case ICER of £10,000 to £15,000/QALY. Relevant data were extracted and presented in a narrative and in tables. Results In total, 15% (26 of 171) of STAs included a company submission with a base-case ICER of less than £10,000/QALY. Of these, 73% (19 of 26) were given positive recommendations after the first Appraisal Committee (AC) meeting, whereas 27% (7 of 26) were initially given a Minded No before receiving a positive recommendation in the final appraisal determination, albeit with restricted recommendations for three technologies. Five STAs had company base-case ICERs of £10,000 to £15,000/QALY and all received a positive recommendation after the first AC meeting. Conclusions Most previous STAs with a company base-case ICER of £10,000 or even £15,000/QALY received a positive recommendation after the first AC meeting, but a number of them proved more complicated and required detailed appraisal, which influenced the final recommendation. This finding might have implications for the proposed fast-track process of the National Institute for Health and Care Excellence.

Item Type:	Article
Uncontrolled Keywords:	base-case ICERs, health policy, National Institute for Health and Care Excellence (NICE), single-technology appraisals (STAB)
Depositing User:	Symplectic Admin
Date Deposited:	29 Nov 2018 08:59
Last Modified:	19 Jan 2023 06:48
DOI:	10.1016/j.jval.2017.09.006
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3013645